Pharmaceutical Market Access in Latin America

Date: August 22, 2010
Pages: 58
Price:
US$ 395.00
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PDA0AD5963AEN
Leaflet:

Download PDF Leaflet

Pharmaceutical Market Access in Latin America
With its top eight markets valued at more than $30 billion in 2009, Latin America represents shining hope for an industry in flux.

Strong, steady growth, resiliency in the face of global downturn, positive regulatory frameworks and a motivated public all translate into one of the world’s leading emerging markets.

Yet, with seven cultural groups, an estimated population of 568 million and every political philosophy from left to right, the region also poses significant barriers. In some countries, such as Columbia, Mexico and Chile, right-of-centre politics mean a favorable regulatory environment and government support. In Venezuela, Ecuador, Bolivia and Nicaragua, however, left-leaning administrations can pose challenges.

And while country members of the Mercosur and Andean groups have joined forces to combine regulations and approval processes, there have been delays along the way. Regulatory frameworks overall have improved as a result of free trade and intellectual property agreements. Yet many administrations—intentionally or not—have promoted the generic industry.

Navigating such a diverse, colourful and dynamic region requires local knowledge, expert insight and up-to-date reporting. In Pharmaceutical Market Access in Latin America, FirstWord offers the roadmap the industry needs to tap into Latin America’s possibilities. The report, which features extensive interviews with industry and government leaders, explains the regulatory, legal and geo-political environment, country by country. The dossier offers up-to-date insights into the use of market access consultants, five case studies of major firms’ experiences and an in-depth breakdown of inter-governmental pharmaceutical agreements, by institution or country.

The report offers insights into:
  • The regulatory, geo-political and economic environment of 10 Latin American regions
  • The increasing use of market access consultants by major pharmaceutical firms

Key features
  • A country-by-country breakdown of major players, newcomers, infrastructure and industry operations
  • Five case studies of major pharmaceutical companies
  • Charts on inter-governmental agreements, legal and national public policy environments
  • Description of attempts to standardize regulations and policy approval processes

Companies profiled in the case studies
  • GSK in Argentina
  • Ranbaxy in six regions
  • Frensenius Medical Care in Columbia
  • Pfizer in Venezuela
  • Bristol-Myers Squibb in Latin America
EXECUTIVE SUMMARY

THE LATIN AMERICAN PHARMACEUTICAL MARKET

THE REGULATORY ENVIRONMENT

IN LATIN AMERICA

THE INCREASING USE OF MARKET ACCESS

CONSULTANTS BY BIG PHARMA FIRMS

DRUG REGISTRATION

LEGAL, REGULATORY, AND GEO-POLITICAL CLIMATES

Latin America overall
  Inter-governmental pharmaceutical agreements
  The pharmaceutical legal environment
  National public policy environments
Argentina
Brazil
Central America
Chile
Colombia
Cuba
Ecuador
Mexico
Peru
Venezuela
Case studies of market entry strategies
  GSK in Argentina
  Ranbaxy across Latin America
    Ranbaxy in Peru
    Ranbaxy in Central America
    Ranbaxy in Venezuela, Ecuador and Colombia
    Ranbaxy in Brazil
    Ranbaxy in Mexico
  Fresenius Medical Care in Colombia
  Pfizer in Venezuela
  Bristol-Myers Squibb in Latin America

INDEX
Skip to top


Branded vs Generics Drugs in Latin America US$ 395.00 Feb, 2010 · 52 pages
Pharma Marketing in Latin America US$ 395.00 Nov, 2010 · 43 pages

Ask Your Question

Pharmaceutical Market Access in Latin America
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: